Xavier Morelli

Has grant

Aix-Marseille University

France

Research Interests

Explore related searches

Professors in France Professors in Cancer Biology Cancer Biology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Probing the biology of BET family subdomain selectivity in onco-hematology. Application and therapeutic interest

Open Date: 2017-12-13

Close Date: 2019-12-12

Grant: Close

Innovating Strategy to modulate Protein-Protein Interaction

Open Date: 2015-10-01

Close Date: 2018-09-30

Articles (11)

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Kristine Schauer

FRANCE

View details

Jean-Paul Borg

Dean, Professor

Aix-Marseille University

FRANCE

View details

Marco Antonio Mendoza-Parra

FRANCE

View details

Yassine Cherrak

Tenure Track Assistant Professor

National University of Singapore

SINGAPORE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Xavier Morelli

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (11)

Discovery of a PDZ Domain Inhibitor Targeting the Syndecan/Syntenin Protein–Protein Interaction: A Semi-Automated “Hit Identification-to-Optimization” Approach

Discovery of Small-Molecule Inhibitors of the PTK7/β-Catenin Interaction Targeting the Wnt Signaling Pathway in Colorectal Cancer

CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation

The NANOTUMOR consortium – Towards the Tumor Cell Atlas

Inhibiting Type VI Secretion System Activity with a Biomimetic Peptide Designed To Target the Baseplate Wedge Complex.

Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread.

Synergy and allostery in ligand binding by HIV-1 Nef.

Rational Design of PDZ Domain Inhibitors: Discovery of Small Organic Compounds Targeting PDZ Domains.

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo.

[Role in oncology and targeting of the PTK7 tyrosine kinase receptor].

Collaborators (4)

Kristine Schauer

Jean-Paul Borg

Marco Antonio Mendoza-Parra

Yassine Cherrak

Make your next move.